SEC Form 4/A · accession 0001209191-17-042113
ENDRA Life Sciences Inc. · NDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Michael Milos Thornton
Officer — Chief Technology Officer
Period of report
Jun 9, 2017
Accepted (ET)
Jun 28, 2017 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001681682
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1,F2 | $4.55 | Jun 9, 2017 | A | 31,960 | A | — | May 12, 2025 | Common Stock | 31,960 | 31,960 | D |
Explanation of responses
- F1These Stock Options become exercisable in three equal annual installments beginning on May 12, 2018.
- F2This amendment is being filed to correct the expiration date of these Stock Options, which was inadvertantly reported as May 12, 2022. The correct expiration date is May 12, 2025.